Posterior reversible encephalopathy syndrome

(Redirected from PRES)

Background

  • Clinical-radiographic syndrome characterized by headache, seizures, visual disturbances, and altered mental status with vasogenic edema predominantly in posterior brain regions[1]
  • Previously known as reversible posterior leukoencephalopathy syndrome (RPLS)
  • Usually reversible with prompt treatment of underlying cause, but can be irreversible if untreated (cytotoxic edema, hemorrhage)
  • Pathophysiology (two proposed mechanisms):
    • Hypertensive theory: severe hypertension exceeds cerebral autoregulation → hyperperfusion → vasogenic edema (posterior brain more vulnerable due to less sympathetic innervation)
    • Endothelial dysfunction theory: direct endothelial injury from toxins, medications, or autoimmune activation → blood-brain barrier disruption → vasogenic edema

Common Causes

Clinical Features

  • Headache (most common presenting symptom)
  • Seizures (60-75% of cases; may be the presenting feature)
  • Visual disturbances: blurred vision, cortical blindness, visual neglect, homonymous hemianopia
  • Altered mental status: confusion, obtundation, decreased alertness
  • Focal neurologic deficits (less common but can occur)
  • Hypertension (present in 70-80% but PRES can occur with normal BP in 20-30% of cases)
  • Nausea, vomiting

Differential Diagnosis

Evaluation

MRI (Diagnostic Study of Choice)

  • MRI with FLAIR and DWI is the gold standard
  • Classic pattern: bilateral, symmetric vasogenic edema in parieto-occipital white matter
  • FLAIR/T2: hyperintense signal in affected regions
  • DWI/ADC: elevated ADC (vasogenic edema) vs restricted diffusion (cytotoxic edema → worse prognosis)
  • Atypical patterns (30-40%): frontal lobe, temporal lobe, cerebellum, brainstem, unilateral, hemorrhagic
  • Hemorrhage occurs in 5-15% of cases (petechial or frank hemorrhage)

CT Head

  • May show hypodensity in posterior regions but sensitivity is low
  • Useful to rule out hemorrhage or ischemic stroke initially
  • If MRI unavailable, CT findings may be suggestive but are often subtle

Labs

  • BMP (renal function, electrolytes)
  • CBC with smear (evaluate for TMA — schistocytes if TTP/HUS)
  • LFTs, LDH, haptoglobin (hemolysis workup)
  • Urinalysis (proteinuria if eclampsia)
  • Magnesium level
  • Drug levels (cyclosporine, tacrolimus)
  • Pregnancy test in reproductive-age women

Management

Blood Pressure Control (If Hypertensive)

  • Gradual reduction — target 25% reduction in MAP in first few hours
  • Avoid precipitous drops (risk of posterior circulation ischemia)
  • Preferred agents:
    • Nicardipine infusion 5-15 mg/hr (easily titratable)
    • Labetalol 10-20 mg IV q10-20min
  • If eclampsia: magnesium sulfate is first-line for seizure prevention (see eclampsia)

Seizure Management

  • Benzodiazepines for acute seizures (lorazepam 2-4 mg IV)
  • AEDs for ongoing seizure prophylaxis (levetiracetam preferred)
  • If eclampsia: magnesium sulfate (primary treatment)
  • Most seizures resolve with BP control and treatment of underlying cause

Treat Underlying Cause

  • Discontinue or reduce offending medication (cyclosporine, tacrolimus, chemotherapy)
  • Delivery for eclampsia/preeclampsia with severe features
  • Treat sepsis, renal failure, autoimmune flare as indicated
  • Dialysis for uremic patients

Monitoring

  • ICU admission for most patients
  • Continuous BP monitoring (arterial line preferred)
  • Serial neurologic exams
  • Repeat MRI at 1-2 weeks to confirm resolution of edema

Prognosis

  • Majority of cases are fully reversible within days to weeks with appropriate treatment
  • Risk factors for poor outcome:
    • Restricted diffusion on DWI (cytotoxic edema → infarction)
    • Hemorrhage
    • Delayed diagnosis and treatment
    • Untreated PRES can progress to permanent brain injury

Disposition

  • Admit to ICU for BP monitoring, seizure management, and neurologic observation
  • Neurology consultation
  • Nephrology if drug-related (immunosuppressant dose adjustment)
  • OB consultation if eclampsia/preeclampsia

See Also

References

  • Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14(9):914-925. PMID 26184985
  • Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol. 2008;29(6):1043-1049. PMID 18403560
  • Hinchey J, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494-500. PMID 8559202
  • Liman TG, et al. Clinical and radiological differences in posterior reversible encephalopathy syndrome between patients with preeclampsia-eclampsia and other predisposing diseases. Eur J Neurol. 2012;19(7):935-943. PMID 22248339
  1. Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14(9):914-925. PMID 26184985